SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Veradigm Inc. (MDRX) , 前瞻盈利收益率 6.46%. PEG 0.54 (Peter Lynch 低估标准 ≤1.0).
本页证实的标准:
- VALUE (100/100, 通过) — PEG ≤ 1.0 — Peter Lynch 低估标准 (0.54); 分析师目标价暗示上行空间 (+260.1%).
- 前瞻市盈率 15.5
- PEG 比率 0.54 — 低于1.0表明股票相对于其盈利增长率被低估（Peter Lynch 标准）。
- 分析师共识目标价 $16.17 (+260.1% 上行空间) — 华尔街分析师认为存在显著上行潜力。
SharesGrow 综合评分： 57/100 其中 1/7 项标准通过。
SharesGrow 7-Criteria Score
✓
价值
100/100
Price-to-Earnings & upside
Proven by this page
~
健康
67/100
Debt-to-Equity & liquidity
→ Health
估值概览 — MDRX
估值倍数
P/E (TTM)0.0
前瞻 P/E15.5
PEG 比率0.54
前瞻 PEG0.54
P/B 比率0.00
P/S 比率0.98
EV/EBITDA0.0
每股数据
EPS (TTM)$-0.67
前瞻 EPS（预估）$0.29
每股账面价值$0.00
每股营收$4.56
每股自由现金流$0.00
收益率与内在价值
盈利收益率N/A
Forward Earnings Yield6.46%
股息收益率0.00%
分析师目标价$16.17 (+260.1%)
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2013 |
$-0.59 |
$1.37B |
$-104.03M |
-7.6% |
| 2014 |
$-0.37 |
$1.38B |
$-66.45M |
-4.8% |
| 2015 |
$-0.01 |
$1.39B |
$-2.23M |
-0.2% |
| 2016 |
$-0.14 |
$1.55B |
$-25.65M |
-1.7% |
| 2017 |
$-1.09 |
$1.5B |
$-196.46M |
-13.1% |
| 2018 |
$2.04 |
$1.75B |
$363.74M |
20.8% |
| 2019 |
$-1.10 |
$1.63B |
$-182.18M |
-11.2% |
| 2020 |
$4.37 |
$1.5B |
$700.41M |
46.6% |
| 2021 |
$1.01 |
$1.5B |
$134.44M |
8.9% |
| 2022 |
$-0.67 |
$588.02M |
$-86.46M |
-14.7% |
